New Oxford Fund to Bridge Innovation Gap
A new Fund launched today by Oxford University will enable donors to support proof of concept and prototyping work to turn more research ideas into commercially-viable technologies, products and services.
The Oxford Invention Fund, which will be managed by Oxford University’s technology transfer company Isis Innovation, is part of Oxford Thinking, the Campaign to raise a minimum of £1.25bn for the collegiate University.
It is widely recognised that there is an ‘innovation gap’ between the early stages of an invention or idea and the point when it is mature enough to be commercialised through a license or spin-out company. The new initiative aims to raise up to £5m to create a self-sustaining fund to help develop Oxford inventions to the point when they can attract commercial investment.
‘Many university-based inventions lack well-developed product prototypes and vital experimental data to help them succeed, and obtaining funds for such work from venture capital providers or research funders is still a problem,’ said Tom Hockaday, Managing Director of Isis Innovation. ‘The aim of this Fund is to support the work needed to make even more Oxford inventions attractive propositions for licensing or investment.’
‘The Oxford Invention Fund provides the opportunity for donors to the University to see their donations used to support innovation and enterprise in Oxford, and to see a return to the University from successful new business ventures,’ said Bernard Taylor, Chairman of Isis Innovation.
Isis Innovation has a long track-record of success in exploiting research discoveries and ideas from Oxford University. In the last ten years Isis has set up 54 new technology spin-out companies, over 90% of which are still in business, and concluded 500 technology licensing transactions. Isis currently manages over 750 technology projects and files on average more than one new patent application each week.
Isis Innovation has managed the highly successful Oxford University Challenge Seed Fund (UCSF) which, since it was first launched in 1999, has awarded £5.7m, financing 102 projects and prompting the formation of 31 spin-out companies and the completion of 51 commercial deals.
The Oxford Invention Fund is modelled after the UCSF, with returns from its investments re-invested in further projects so that it can continue to support innovation at Oxford for many years to come. It is hoped that one day money generated from the Fund could be used to subsidise scholarships and bursaries to help the next generation of inventors and scientists.
For Business Planning and Fund Raising Services Click Here
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
For Assistance with Regulatory Planning and Exicution of Clinical Trials Click Here
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!
Fill Out the Short Form Below… |
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
